Cardio Diagnostics Holdings (CDIO) Restructuring Costs (2022)
Cardio Diagnostics Holdings (CDIO) posted Restructuring Costs of $55034.0 for Q2 2022, down 4.29% sequentially from $57500.0 in Q1 2022.
Cardio Diagnostics Holdings (CDIO) Restructuring Costs (2022) Analysis & Trends
Cardio Diagnostics Holdings has reported Restructuring Costs for 1 years, with the latest figure at $55034.0 in Q2 2022.
- Quarterly Restructuring Costs changed N/A year-over-year to $55034.0 in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $55034.0 (changed N/A YoY) and the FY2022 annual result came in at $112534.0, changed N/A from the prior year.
- Restructuring Costs slipped to $55034.0 in Q2 2022 per CDIO's latest filing, from $57500.0 in the prior quarter.
- Over five years, Restructuring Costs peaked at $57500.0 in Q1 2022 and troughed at $55034.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 55,034.00 |
| Mar 31, 2022 | 57,500.00 |